PE20090329A1 - Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos - Google Patents

Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Info

Publication number
PE20090329A1
PE20090329A1 PE2008000921A PE2008000921A PE20090329A1 PE 20090329 A1 PE20090329 A1 PE 20090329A1 PE 2008000921 A PE2008000921 A PE 2008000921A PE 2008000921 A PE2008000921 A PE 2008000921A PE 20090329 A1 PE20090329 A1 PE 20090329A1
Authority
PE
Peru
Prior art keywords
cdr
containing seq
globulomer
antibodies against
humanized antibodies
Prior art date
Application number
PE2008000921A
Other languages
English (en)
Inventor
Stefan Barghorn
Heinz Hillen
Patrick Keller
Andreas R Striebinger
Boris Labkovsky
Paul R Hinton
Veronica M Juan
Original Assignee
Abbott Lab
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39791050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090329(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab, Abbott Gmbh & Co Kg filed Critical Abbott Lab
Publication of PE20090329A1 publication Critical patent/PE20090329A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA PROTEINA DE UNION TAL COMO UNA MOLECULA DE INMUNOGLOBULINA, UN ANTICUERPO MONOCLONAL, UN ANTICUERPO HUMANIZADO, UN Fab, ENTRE OTROS, QUE COMPRENDE UN DOMINIO DE UNION A ANTIGENO QUE SE UNE AL GLOBULOMERO BETA AMILOIDE(20-42) QUE COMPRENDE UNA CDR CUYA SECUENCIA DE AMINOACIDOS CONSISTE EN: A) CDR-VH1 QUE CONTIENE LA SEC ID Nº 5; B) CDR-VH2 QUE CONTIENE LA SEC ID Nº 6; C) CDR-VH3 QUE CONTIENE LA SEC ID Nº 7; D) CDR-VL1 QUE CONTIENE LA SEC ID Nº 8; E) CDR-VL2 QUE CONTIENE LA SEC ID Nº 9; CDR-VL3 QUE CONTIENE LA SEC ID Nº 10. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHA PROTEINA DE UNION O UN ANTICUERPO CONJUGADO EN FORMA DE CRISTAL, SIENDO UTIL EN EL TRATAMIENTO Y DIAGNOSTICO DE LA ENFERMEDAD DE ALZHEIMER
PE2008000921A 2007-05-30 2008-05-29 Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos PE20090329A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94093207P 2007-05-30 2007-05-30
US99035907P 2007-11-27 2007-11-27

Publications (1)

Publication Number Publication Date
PE20090329A1 true PE20090329A1 (es) 2009-03-27

Family

ID=39791050

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000921A PE20090329A1 (es) 2007-05-30 2008-05-29 Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos

Country Status (22)

Country Link
US (1) US20090175847A1 (es)
EP (1) EP2150563A1 (es)
JP (1) JP2010530740A (es)
KR (1) KR20100032398A (es)
CN (1) CN101827862A (es)
AR (1) AR066794A1 (es)
AU (1) AU2008260062A1 (es)
BR (1) BRPI0812005A2 (es)
CA (1) CA2687414A1 (es)
CL (1) CL2008001580A1 (es)
CO (1) CO6251291A2 (es)
CR (1) CR11179A (es)
DO (1) DOP2009000269A (es)
EC (1) ECSP099833A (es)
IL (1) IL202243A0 (es)
MX (1) MX2009012950A (es)
PA (1) PA8782201A1 (es)
PE (1) PE20090329A1 (es)
RU (1) RU2009149370A (es)
TW (1) TW200914465A (es)
UY (1) UY31114A1 (es)
WO (1) WO2008150949A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
BRPI0506629A (pt) * 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
US20070045902A1 (en) 2004-07-13 2007-03-01 Brauker James H Analyte sensor
US8989833B2 (en) 2004-07-13 2015-03-24 Dexcom, Inc. Transcutaneous analyte sensor
PT2343380T (pt) * 2004-11-16 2019-09-18 Humanigen Inc Permuta de cassetes da região variável de imunoglobulina
WO2006128006A1 (en) * 2005-05-26 2006-11-30 The Regents Of The University Of Colorado Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
CN101668773B (zh) 2007-03-14 2016-08-31 亚力史制药公司 人工程化抗b因子抗体
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2116556B1 (en) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2013202020B2 (en) * 2009-07-31 2014-11-27 F. Hoffmann-La Roche Ag Subcutaneous anti-HER2 antibody formulation
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
KR20130010123A (ko) * 2010-04-07 2013-01-25 아비에 인코포레이티드 ＴＮＦ-α 결합 단백질
US8987419B2 (en) * 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CN102516360B (zh) * 2011-12-08 2013-11-06 清华大学 一种抑制β分泌酶酶切作用的多肽及其应用
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
SMT202000340T1 (it) 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
JP2017512751A (ja) * 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CA3004152C (en) 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
CN115175932B (zh) * 2019-07-16 2025-10-31 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途
CN117491650B (zh) * 2023-11-01 2024-09-20 首都医科大学宣武医院 一种外周血Hb-Aβ复合物定量检测试剂盒、检测方法及应用
WO2025228315A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529938A (en) * 1983-02-14 1985-07-16 Shell Oil Company High frequency induction method for locating the interface between formations having the same resistivity
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
DE229046T1 (de) * 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US6492107B1 (en) * 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) * 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5780225A (en) * 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) * 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5698426A (en) * 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) * 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) * 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2109528A1 (en) * 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
EP0571613B1 (en) * 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US5934272A (en) * 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5565352A (en) * 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
US5516637A (en) * 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU705616B2 (en) * 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
JP2978435B2 (ja) * 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE508733T1 (de) * 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2252261T3 (es) * 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
DK2093286T3 (da) * 2001-10-01 2013-05-13 Dyax Corp Flerkædede, eukaryote displayvektorer og anvendelser deraf
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005035575A2 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1879613B1 (en) * 2005-05-05 2011-11-30 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease

Also Published As

Publication number Publication date
CR11179A (es) 2010-05-27
CO6251291A2 (es) 2011-02-21
KR20100032398A (ko) 2010-03-25
CL2008001580A1 (es) 2008-12-05
MX2009012950A (es) 2010-03-26
AR066794A1 (es) 2009-09-09
ECSP099833A (es) 2010-01-29
WO2008150949A1 (en) 2008-12-11
CN101827862A (zh) 2010-09-08
IL202243A0 (en) 2010-06-16
DOP2009000269A (es) 2009-12-15
US20090175847A1 (en) 2009-07-09
UY31114A1 (es) 2009-01-05
CA2687414A1 (en) 2008-12-11
AU2008260062A1 (en) 2008-12-11
RU2009149370A (ru) 2011-07-10
TW200914465A (en) 2009-04-01
PA8782201A1 (es) 2009-02-09
EP2150563A1 (en) 2010-02-10
BRPI0812005A2 (pt) 2019-09-24
JP2010530740A (ja) 2010-09-16

Similar Documents

Publication Publication Date Title
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
PE20120415A1 (es) Anticuerpos anti-igf
PE20211217A1 (es) Anticuerpos estabilizadores de trem2
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20090368A1 (es) Anticuerpos anti-igf
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
PE20131209A1 (es) Anticuerpos anti-fap
UY30524A1 (es) Anticuerpos dirigidos a avb(beta)6 y sus usos
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
PE20121397A1 (es) Anticuerpos especificos para cadherina-17
PE20161327A1 (es) Proteinas de enlace al antigeno il-23 humana
PE20071055A1 (es) Anticuerpos anti mn
AR072167A1 (es) Anticuerpos contra il-6 humano y sus usos

Legal Events

Date Code Title Description
FD Application declared void or lapsed